MedKoo product information:

  ALB-109564

Description of ALB109564: ALB 109564(a) is a semi-synthetic derivative of the vinka alkaloid vinblastine with potential antineoplastic activity. Tubulin inhibitor ALB 109564(a) binds to tubulin monomers and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the G2/M phase of the cell cycle. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Current developer:    Albany Molecular Research, Inc., AMRI

ALB 109564(a) is a novel analog from an established and marketed class of tubulin inhibitors, which is designed to kill cancer cells by preventing cell mitosis. In preclinical testing, the compound has a broad-spectrum effect in animal models, with efficacy superior to vinorelbine. Significant tumor growth delay was seen against human colon, lung and prostate solid tumors (as xenografts in mice) and against leukemia in mice. (source: http://www.amriglobal.com/pipeline/subpage.cfm?ID=19&subID=32).

ALB 109564(a) is an antimitotic agent and a semi-synthetic derivative of a natural product originally extracted from the Madagascar periwinkle flower. Antimitotic agents, used alone or most commonly in combination, continue to be an important part of cancer therapy; AMRI's tubulin inhibitor has potential to broaden this current arsenal. (source: http://www.amriglobal.com/pipeline/subpage.cfm?ID=19&subID=32).

Structures were from: AMRI 's website.

1: Milanowski DJ, Keilman J, Guo C, Mocek U. Isolation and identification of five impurities of ALB 109564(a) drug substance. J Pharm Biomed Anal. 2011 May 15;55(2):366-72. Epub 2011 Feb 3. PubMed PMID: 21353428.